Hydrocinnamyl Alcohol

Hydrocinnamyl Alcohol

SCHEMBL5741728

CC(C)(C)OC(N)=O.OCCCc1ccccc1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
PPARA Q07869 1/20 0.50
NR1H2 P55055 1/20 0.48
LTA4H P09960 1/20 0.46
EPHX2 P34913 1/20 0.46
POLB P06746 1/20 0.45
CYP4A11 Q02928 2/20 0.44
HDAC3 O15379 1/20 0.43
MAPK1 P28482 1/20 0.43
ADRA1A P35348 1/20 0.43
HDAC4 P56524 1/20 0.43
SLC6A3 Q01959 1/20 0.43
HDAC1 Q13547 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22042153 0.86 LMNA (0.51) LMNAPOLBHDAC3MAPK1ADRA1A
SCHEMBL22042158 0.84 LMNA (0.47) LMNAPOLBHDAC3HDAC1HDAC2
Phenyl Propionic Acid SCHEMBL7261317 0.83 KEAP1 (0.61) LMNANR1H2HDAC3MAPK1ADRA1A
Hydrocinnamyl Alcohol SCHEMBL27682093 0.81 LMNA (0.58) LMNALTA4HEPHX2HDAC3MAPK1
Hydrocinnamyl Alcohol SCHEMBL28223376 0.81 LMNA (0.58) LMNALTA4HEPHX2HDAC3MAPK1
Hydrocinnamyl Alcohol SCHEMBL28266054 0.81 PPARA (0.47) PPARANR1H2LTA4HEPHX2POLB
Ethylbenzene SCHEMBL27571280 0.80 TP53 (0.50) LMNAPPARATDP1KMT2AMAPT
SCHEMBL5756427 0.80 CTSK (0.47) LMNAKMT2ACTSS
SCHEMBL27571279 0.79 LMNA (0.54) LMNAPOLBHDAC3MAPK1ADRA1A
Hydrocinnamyl Alcohol SCHEMBL27852102 0.79 LMNA (0.63) LMNAPPARALTA4HEPHX2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111285850-B Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2022-04-22 CN disclosed
US-20220041578-A1 ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2022-02-10 US disclosed
EP-3896062-A1 ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2021-10-20 EP disclosed
CN-111285850-A Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2020-06-16 CN disclosed
WO-2020114482-A1 ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND 中国科学院上海药物研究所 2020-06-11 WO disclosed
EP-1358183-B1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2006-04-12 EP disclosed
US-20050070598-A1 Cysteine protease inhibitors MEDIVIR AB (SE) 2005-03-31 US disclosed
US-20050020588-A1 Cysteine protease inhibitors PEPTIMMUNE, INC. 2005-01-27 US disclosed
US-20040229915-A1 Cysteine protease inhibitors MEDIVIR AB (SE) 2004-11-18 US disclosed
EP-1413580-A1 Furanone derivatives as inhibitors of Cathepsin S Medivir UK Ltd (GB) 2004-04-28 EP disclosed
EP-1178986-B1 FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S MEDIVIR UK LTD (GB) 2004-02-25 EP disclosed
US-20030203900-A1 Cysteine protease inhibitors MEDIVIR UK LTD (GB) 2003-10-30 US disclosed
US-20030186962-A1 Cysteine protease inhibitors MEDIVIR AB (SE) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186962-A1 Cysteine protease inhibitors C1R, CTSS, CTSZ LMNA 1883/4885PPARA 4026/4885NR1H2 860/4885
US-20050070598-A1 Cysteine protease inhibitors CTRL, CTSZ, CTSS LMNA 3195/4885PPARA 3672/4885NR1H2 1544/4885
US-20050020588-A1 Cysteine protease inhibitors CTSS, CTSE, CTSV LMNA 3301/4885PPARA 3801/4885NR1H2 2751/4885
US-20220041578-A1 ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND CRBN, CUL4B, UBQLN1 LMNA 2811/4885PPARA 4495/4885NR1H2 331/4885
US-20040229915-A1 Cysteine protease inhibitors C1R, CTRL, CTSK LMNA 3004/4885PPARA 4589/4885NR1H2 937/4885
US-20030203900-A1 Cysteine protease inhibitors CTSS, CTSE, CTSV LMNA 3301/4885PPARA 3801/4885NR1H2 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.